Diabetes Research and Clinical Practice
Volume 88, Issue 2 , Pages e17-e19 , May 2010

Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration

Received 30 June 2009 ,Revised 9 January 2010 ,Accepted 18 January 2010.

References 

  1. Sanofi-Aventis U.S. LLC. Lantus® package insert, Bridgewater, NJ, March (2007).
  2. Idampitiya C, Ward K, Curtis C, Fernando DJS, Idris I, Thomson GA. Once daily insulin glargine may induce loss of basal insulin action in some patients with type 1 diabetes receiving basal bolus regimens: the need for twice daily glargine. Diabetes. 2005;54(Suppl. 1):A493;(abstract)
  3. Albright ES, Desmond R, Bell DSH. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27(2):632–633(letter)
  4. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  5. McCord AD, Kiel PJ, Deurloo D, Zgarrick DP. Insulin glargine: clinical efficacy and predictors of twice daily dosing. Pharmacotherapy. 2005;25(10):1454;(abstract 99)

PII: S0168-8227(10)00043-4

doi: 10.1016/j.diabres.2010.01.020

Diabetes Research and Clinical Practice
Volume 88, Issue 2 , Pages e17-e19 , May 2010

Article Tools

* Image Usage & Resolution